Back to results
US 12,611,409 B2Granted
Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
AssigneeChemoCentryx, Inc.
InventorsJames J. Campbell, Zhenhua Miao, Thomas J. Schall, Israel Charo, Shijie Li, Christine Marie Janson, Rajinder Singh, Karen Ebsworth
Life of this patent
Estimating the term…
Abstract
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
Claims13
A method of treating cancer in a mammal, said method comprising administering a therapeutically effective amount of a CCR2 chemokine receptor antagonist and a therapeutically effective amount of a PD-1 and/or PD-L1 inhibitor, wherein said CCR2 chemokine receptor antagonist is Compound 1
- or a pharmaceutically acceptable salt thereof;
- wherein said cancer is glioma;
- and
- wherein the PD-1 inhibitor is pembrolizumab or nivolumab and the PD-L1 inhibitor is durvalumab, atezolizumab, or avelumab.
1 more element
Dependencies are inferred from the claim text.